The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma:: A comparative study

被引:100
作者
Ordóñez, NG [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
关键词
mesothelioma; pleura; kidney; renal cell carcinoma; immunohistochemistry; calretinin; cytokeratin; 5/6; mesothelin; WT1; thrombomodulin; CD10; CD15; carcinoembryonic antigen; Ber-EP4; B72.3; BG-8; N-cadherin; MOC-31; renal cell carcinoma marker;
D O I
10.1016/j.humpath.2003.11.013
中图分类号
R36 [病理学];
学科分类号
100104 [病理学与病理生理学];
摘要
Both mesotheliomas and renal cell carcinomas can present a wide variety of morphological patterns. Because of this, renal cell carcinomas that metastasize to the pleura and lung may be confused with mesotheliomas. The aim of the present study was to compare the value of the various immunohistochemical markers currently available for the diagnosis of mesothelioma and renal cell carcinoma. A total of 48 mesotheliomas (40 epithelioid, 8 sarcomatoid), and 48 renal cell carcinomas (24 conventional, 12 chromophobe, 8 papillary, 4 sarcomatoid) were investigated for the expression of the following markers: calretinin, mesothelin, cytokeratin 5/6, WT1, thrombomodulin (TM), N-cadherin, CD15 (leu-M1), MOC-31, Ber-EP4, BG-8 (Lewis(y)), CD10, renal cell carcinoma marker (RCC Ma), carcinoembryonic antigen (CEA), and B72.3. All (100%) of the epithelioid mesotheliomas reacted for calretinin, mesothelin, and cytokeratin 5/6; 93% for WT1; 78% for TM; 75% for N-cadherin, 48% for CD10, 15% for Ber-EP4, 8% for MOC-31,8% for RCC Ma, 5% for BG-8, and none for CEA, B72.3, or CD15. Of the sarcomatoid mesotheliomas, 88% expressed calretinin, 75% N-cadherin, 38% CD10, and 13% each expressed cytokeratin 5/6, WT1, and TM. All of the remaining markers were negative. Among the RCCs, 81% expressed CD10, 75% N-cadherin, 63% CD15, 50% RCC Ma, 50% MOC-31, 42% Ber-EP4, 8% BG-8, and 2% TM. The remaining markers were negative. The results indicate that calretinin, mesothelin, and cytokeratin 5/6 are the best positive mesothelioma markers for differentiating epithelioid mesotheliomas from renal cell carcinomas. The best discriminators among the antibodies considered negative markers for mesothelioma are CD15, MOC-31, and RCC Ma. An accurate differential diagnosis can be reached with the use of any 2 of the 3 recommended positive markers, which should be selected based on availability and on which ones yield the best staining results in a given laboratory. One of the recommended negative markers may be added to the panel if deemed necessary. If confirmation of renal origin is needed, RCC Ma could be useful. Calretinin is the only marker that appears to have any utility in distinguishing between sarcomatoid mesotheliomas and sarcomatoid renal cell carcinomas. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:697 / 710
页数:14
相关论文
共 100 条
[1]
Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies [J].
Abutaily, AS ;
Addis, BJ ;
Roche, WR .
JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 (09) :662-668
[2]
AMEILLE J, 1993, REV MAL RESPIR, V10, P42
[3]
[Anonymous], ADV ANAT PATHOL
[4]
CD10 - A review [J].
Arber, DA ;
Weiss, LM .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 1997, 5 (03) :125-140
[5]
A COMPARATIVE IMMUNOHISTOCHEMICAL STUDY OF MALIGNANT MESOTHELIOMA AND RENAL-CELL CARCINOMA - THE DIAGNOSTIC UTILITY OF LEU-M1, BER EP4, TAMM-HORSFALL PROTEIN AND THROMBOMODULIN [J].
ATTANOOS, RL ;
GODDARD, H ;
THOMAS, ND ;
JASANI, B ;
GIBBS, AR .
HISTOPATHOLOGY, 1995, 27 (04) :361-366
[6]
Mesothelioma-binding antibodies: Thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma [J].
Attanoos, RL ;
Goddard, H ;
Gibbs, AR .
HISTOPATHOLOGY, 1996, 29 (03) :209-215
[7]
Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms [J].
Attanoos, RL ;
Dojcinov, SD ;
Webb, R ;
Gibbs, AR .
HISTOPATHOLOGY, 2000, 37 (03) :224-231
[8]
Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms [J].
Avery, AK ;
Beckstead, J ;
Renshaw, AA ;
Corless, CL .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2000, 24 (02) :203-210
[9]
Azuma T, 1999, SCAND J UROL NEPHROL, V33, P140
[10]
Barberis MCP, 1997, ACTA CYTOL, V41, P1757